At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

被引：0
|
作者：
Cohn, D. [1 ]
Kim, K. [2 ]
Resnick, K. [1 ]
O'Malley, D. [1 ]
Straughn, J. [2 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Univ Alabama, Birmingham, AL USA
来源：
GYNECOLOGIC ONCOLOGY | 2010年 / 116卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
28
引用
收藏
页码：S12 / S13
页数：2
相关论文
共 50 条
  • [1] At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
    Cohn, David E.
    Kim, Kenneth H.
    Resnick, Kimberly E.
    O'Malley, David M.
    Straughn, J. Michael, Jr.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) : 1247 - 1251
  • [2] Cost-effectiveness of a predictive biomarker for bevacizumab responsiveness in the primary treatment of ovarian cancer
    Barnett, I.
    Alvarez-Secord, A.
    Cohn, D.
    Leath, C.
    Peterson, B.
    Myers, E.
    Havrilesky, L.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 : S66 - S66
  • [3] The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada
    Duong, M.
    Wright, E.
    Yin, L.
    Martin-Nunez, I.
    Ghatage, P.
    Fung-Kee-Fung, M.
    [J]. CURRENT ONCOLOGY, 2016, 23 (05) : E461 - E467
  • [4] Bevacizumab in Treatment of High-Risk Ovarian Cancer-A Cost-Effectiveness Analysis
    Chan, John K.
    Herzog, Thomas J.
    Hu, Lilian
    Monk, Bradley J.
    Kiet, Tuyen
    Blansit, Kevin
    Kapp, Daniel S.
    Yu, Xinhua
    [J]. ONCOLOGIST, 2014, 19 (05): : 523 - 527
  • [5] BEVACIZUMAB FOR THE TREATMENT OF METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS
    Fortune-Greeley, A.
    Cornell, P.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A34 - A34
  • [6] Cost Effectiveness of Alternative Strategies for Incorporating Bevacizumab Into the Primary Treatment of Ovarian Cancer
    Barnett, Jason C.
    Secord, Angeles Alvarez
    Cohn, David E.
    Leath, Charles A., III
    Myers, Evan R.
    Havrilesky, Laura J.
    [J]. CANCER, 2013, 119 (20) : 3653 - 3661
  • [7] An economic analysis: Examining the cost-effectiveness of bevacizumab and olaparib as upfront maintenance treatment of advanced ovarian cancer
    Wolford, J. E.
    Liang, S. Y.
    Tewari, K. S.
    Eskander, R. N.
    Kapp, D. S.
    Mann, A. K.
    Chan, J. K.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 25 - 25
  • [8] Do rheumatology cost-effectiveness analyses make sense?
    Wolfe, F
    Michaud, K
    Pincus, T
    [J]. RHEUMATOLOGY, 2004, 43 (01) : 4 - 6
  • [9] Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K. W.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher R.
    Hall, Peter S.
    [J]. ONCOLOGIST, 2017, 22 (06): : 694 - 699
  • [10] WHAT IS COST-EFFECTIVENESS ANALYSIS
    EVANS, DB
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1990, 153 : S7 - S9
12345